spacer
home > epc > winter 2003 > extending a patent portfolio
PUBLICATIONS
European Pharmaceutical Contractor

Extending a Patent Portfolio

The pharmaceutical sector is struggling to maintain stock price stability in light of a gap in the drug development pipelines. This article examines some of the strategies available to pharmaceutical companies in order to extend the life of a patent.

The pharmaceutical industry has a very mature appreciation of the strong link between patent protection and the bottom line. No serious player can afford to risk undermining its heavy investment in research and development by allowing major inventions and developments to be copied by competitors. The share prices for pharmaceutical companies have a very close correlation to the life cycle of their drugs, be it in the research and development phase, the launch of products to market or when the patent on a drug approaches the end of its protection, at which point competitors can market their own versions of the drug. As the patent nears the end of its life, analysts will adjust the value of the stock accordingly. Of course, the first thing analysts are interested in is whether the pharmaceutical company can demonstrate stability in sales through a healthy development pipeline.

However, with many patents on major drugs set to expire over the next decade, some of the larger players in the sector are facing increasing scrutiny and pressure to demonstrate shareholder value. One famous case of the massive impact that patent protection can have on a share price is that of Eli Lilly and Prozac®. As the developer of a high profile drug with a large sales volume, Eli Lilly was much lauded in the financial markets. Sales of Prozac reached $2.6 billion per year, and the stock was riding high. This success abruptly ended in August 2000 when, with three years to run on the Prozac patents, a US court effectively held the patents invalid, allowing competitors to bring generic versions to market a lot earlier than expected.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Graham Ruffles, Chartered Patent Attorney and European Patent Attorney at Marks & Clerk

Graham Ruffles is a Chartered Patent Attorney and European Patent Attorney and has been a partner at Marks & Clerk for over 20 years. He graduated in Natural Sciences and subsequently obtained degrees in Organic Chemistry and Biology. He is a European Chemist, a Fellow of the Royal Society of Chemistry and a Chartered Chemist, as well as being a European Biologist, a Member of the Institute of Biology and a Chartered Biologist. During his time at Marks & Clerk, he has gained significant experience of chemical, pharmaceutical and biotechnology patents and related subjects, including medical equipment, polymers and food technology.

spacer
Graham Ruffles
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Joins the Association of Clinical Research Organizations (ACRO) to Add a Technology Perspective to Conversations with Legislators and Industry Leaders about the Future of Clinical Research

PHILADELPHIA, PA – November 21, 2019: Signant Health announced today that it has joined the non-profit Association of Clinical Research Organizations (ACRO). ACRO, a global coalition of research and technology companies, makes it their mission to advocate as the collective voice of the innovative clinical research industry to regulators and policymakers, educating stakeholders and shaping policies that foster efficient, effective and safe conduct of clinical research.
More info >>

White Papers

Systems Engineering for Complex Portable Medical Device Development

Phillips-Medisize

As the demand for complex, portable medical devices continues to grow, reducing risk and increasing efficiency during the development of these products should be paramount. Taking a systems-engineering (SE) approach to development provides a holistic, organized, and deliberate method for identifying as well as reducing both patient and business risks early in the process. Furthermore, it facilitates efficient progression throughout the entire product development life cycle.
More info >>

 
Industry Events

World Vaccine Congress Washington

7-9 April 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement